Tecentriq

View All

Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche's Tecentriq Results in NSCLC
Evotec, Takeda Deal; AZ COVID Vaccine US Trials; Promega’s Recognition; Roche’s Tecentriq Results in NSCLC

Promega Biotech Ibérica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ibérica has been heralded as the business leader in Spain for its COVID-19 response. The company’s innovative approach to deal with COVID-19 and pandemic has led La Razón, a daily newspaper based in Madrid, to felicitate the...

Find More

Non-Small Cell Lung Cancer Market Insights
Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses

Non-small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030. Worldwide, cancer claimed the lives of approximately 9.6 million people in 2018 as per WHO, with lung cancer being the most commonly diagnosed one and accounting for the highest number of deaths (1.76...

Find More

Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval

Bristol-Meyers Squibb and Acceleron Pharma have announced that US FDA committee will review BMS’s supplemental Biologics License Application (sBLA) for its Reblozyl in MDS. Reblozyl ((luspatercept-aamt) has recently been approved by the regulatory authority to cure a rare type of blood disorder, Beta-thalassemi...

Find More

Novo petitions FDA;J&J invests; Xarelto’s trial; Roche’s Tecentriq

Novo petitions FDA to require copies of Victoza to conduct clinical trials With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish drugmaker has filed a citizen petition arg...

Find More